- Founded: 2011
- CEO: William Stilley
- Funding Source: Investor Funded, Publicly Traded, Venture Captital/Private Equity
- Development Stage: Phase 3 Clinical Trial
ADial Pharmaceuticals is focused on developing novel and effective medications to treat addiction and related disorders. Our most advanced compound AD04 specifically targets Alcohol Use Disorder through a proprietary dosage. Furthermore, with a simple blood test, a proprietary genetic bio-marker can identify those patients that would be expected to respond to treatment with AD04 (approximately 35% of patients). AD04 was tested in a Phase IIb study in 283 patients and was shown to be effective against both the primary and secondary end points (p<0.05). AD04 is currently being positioned to commence Phase III trials. ADial also has other products in Phase II and early-stage development.